Inhibition of 6-Phosphogluconate Dehydrogenase Reverses Epirubicin Resistance Through Metabolic Reprograming in Triple-Negative Breast Cancer Cells.

Xu, Jiali; Ren, Guosheng; Cheng, Qiao

Xu, Jiali; Ren, Guosheng; Cheng, Qiao.

Afiliação

Xu J; Department of Breast and Thyroid Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Ren G; Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Cheng Q; Department of Breast and Thyroid Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Technol Cancer Res Treat ; 22: 15330338231190737, 2023.

Article em En | MEDLINE | ID: mdl-37559469

Assuntos

Fosfogluconato Desidrogenase; Neoplasias de Mama Triplo Negativas; Humanos; Epirubicina/farmacologia; Linhagem Celular Tumoral; Fosfogluconato Desidrogenase/genética; Fosfogluconato Desidrogenase/metabolismo; Neoplasias de Mama Triplo Negativas/tratamento farmacológico; Neoplasias de Mama Triplo Negativas/genética; NADP/metabolismo; NADP/farmacologia; Lactatos/farmacologia; Proliferação de Células

Palavras-chave

6PGD; chemotherapy resistance; epirubicin; metabolic reprograming; triple-negative breast cancer (TNBC)

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fosfogluconato Desidrogenase / Neoplasias de Mama Triplo Negativas Limite: Humans Idioma: En Revista: Technol Cancer Res Treat Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google